ER Negative is an inclusion criterion in 470 clinical trials for breast carcinoma, of which 317 are open and 153 are closed. Of the trials that contain ER Negative and breast carcinoma as inclusion criteria, 9 are early phase 1 (6 open), 151 are phase 1 (85 open), 105 are phase 1/phase 2 (75 open), 164 are phase 2 (117 open), 3 are phase 2/phase 3 (3 open), 27 are phase 3 (22 open), and 11 are no phase specified (9 open) [5].

Atezolizumab, nab-paclitaxel, pembrolizumab, and sacituzumab govitecan have evidence of efficacy in patients with ER Negative in breast carcinoma [5].

ER Negative is an inclusion criterion in 109 clinical trials for malignant solid tumor, of which 71 are open and 38 are closed. Of the trials that contain ER Negative and malignant solid tumor as inclusion criteria, 67 are phase 1 (38 open), 33 are phase 1/phase 2 (25 open), and 9 are phase 2 (8 open) [5].

ER Negative is an inclusion criterion in 98 clinical trials for non-small cell lung carcinoma, of which 63 are open and 35 are closed. Of the trials that contain ER Negative and non-small cell lung carcinoma as inclusion criteria, 54 are phase 1 (30 open), 30 are phase 1/phase 2 (21 open), 13 are phase 2 (11 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 81 clinical trials for ovarian carcinoma, of which 53 are open and 28 are closed. Of the trials that contain ER Negative and ovarian carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 46 are phase 1 (23 open), 24 are phase 1/phase 2 (20 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 56 clinical trials for colorectal carcinoma, of which 36 are open and 20 are closed. Of the trials that contain ER Negative and colorectal carcinoma as inclusion criteria, 34 are phase 1 (20 open), 17 are phase 1/phase 2 (13 open), 4 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 54 clinical trials for head and neck squamous cell carcinoma, of which 39 are open and 15 are closed. Of the trials that contain ER Negative and head and neck squamous cell carcinoma as inclusion criteria, 32 are phase 1 (21 open), 17 are phase 1/phase 2 (14 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 45 clinical trials for melanoma, of which 29 are open and 16 are closed. Of the trials that contain ER Negative and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 25 are phase 1 (15 open), 9 are phase 1/phase 2 (7 open), 9 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 41 clinical trials for gastric carcinoma, of which 25 are open and 16 are closed. Of the trials that contain ER Negative and gastric carcinoma as inclusion criteria, 22 are phase 1 (11 open), 12 are phase 1/phase 2 (9 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 37 clinical trials for urothelial carcinoma, of which 26 are open and 11 are closed. Of the trials that contain ER Negative and urothelial carcinoma as inclusion criteria, 19 are phase 1 (11 open), 13 are phase 1/phase 2 (10 open), and 5 are phase 2 (5 open) [5].

ER Negative is an inclusion criterion in 35 clinical trials for renal cell carcinoma, of which 23 are open and 12 are closed. Of the trials that contain ER Negative and renal cell carcinoma as inclusion criteria, 19 are phase 1 (9 open), 10 are phase 1/phase 2 (8 open), 5 are phase 2 (5 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 32 clinical trials for endometrial carcinoma, of which 25 are open and 7 are closed. Of the trials that contain ER Negative and endometrial carcinoma as inclusion criteria, 17 are phase 1 (14 open), 13 are phase 1/phase 2 (9 open), and 2 are phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 32 clinical trials for fallopian tube carcinoma, of which 21 are open and 11 are closed. Of the trials that contain ER Negative and fallopian tube carcinoma as inclusion criteria, 22 are phase 1 (12 open), 7 are phase 1/phase 2 (6 open), and 3 are phase 2 (3 open) [5].

ER Negative is an inclusion criterion in 32 clinical trials for invasive breast carcinoma, of which 30 are open and 2 are closed. Of the trials that contain ER Negative and invasive breast carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 4 are phase 1 (3 open), 21 are phase 2 (20 open), 1 is phase 2/phase 3 (1 open), 3 are phase 3 (3 open), and 1 is no phase specified (1 open) [5].

ER Negative is an inclusion criterion in 31 clinical trials for small cell lung carcinoma, of which 24 are open and 7 are closed. Of the trials that contain ER Negative and small cell lung carcinoma as inclusion criteria, 14 are phase 1 (9 open), 13 are phase 1/phase 2 (11 open), and 4 are phase 2 (4 open) [5].

ER Negative is an inclusion criterion in 29 clinical trials for pancreatic carcinoma, of which 22 are open and 7 are closed. Of the trials that contain ER Negative and pancreatic carcinoma as inclusion criteria, 16 are phase 1 (11 open), 11 are phase 1/phase 2 (9 open), and 2 are phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 29 clinical trials for primary peritoneal carcinoma, of which 18 are open and 11 are closed. Of the trials that contain ER Negative and primary peritoneal carcinoma as inclusion criteria, 20 are phase 1 (10 open), 6 are phase 1/phase 2 (5 open), and 3 are phase 2 (3 open) [5].

ER Negative is an inclusion criterion in 26 clinical trials for cervical carcinoma, of which 22 are open and 4 are closed. Of the trials that contain ER Negative and cervical carcinoma as inclusion criteria, 17 are phase 1 (14 open), 7 are phase 1/phase 2 (6 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 26 clinical trials for prostate carcinoma, of which 16 are open and 10 are closed. Of the trials that contain ER Negative and prostate carcinoma as inclusion criteria, 15 are phase 1 (6 open), 8 are phase 1/phase 2 (7 open), and 3 are phase 2 (3 open) [5].

ER Negative is an inclusion criterion in 24 clinical trials for bladder carcinoma, of which 14 are open and 10 are closed. Of the trials that contain ER Negative and bladder carcinoma as inclusion criteria, 15 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 24 clinical trials for hepatocellular carcinoma, of which 20 are open and 4 are closed. Of the trials that contain ER Negative and hepatocellular carcinoma as inclusion criteria, 13 are phase 1 (10 open), 9 are phase 1/phase 2 (8 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 23 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 17 are open and 6 are closed. Of the trials that contain ER Negative and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 13 are phase 1 (8 open), 7 are phase 1/phase 2 (6 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 20 clinical trials for esophageal carcinoma, of which 14 are open and 6 are closed. Of the trials that contain ER Negative and esophageal carcinoma as inclusion criteria, 7 are phase 1 (3 open), 10 are phase 1/phase 2 (9 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 16 clinical trials for breast adenocarcinoma, of which 15 are open and 1 is closed. Of the trials that contain ER Negative and breast adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 4 are phase 3 (4 open) [5].

ER Negative is an inclusion criterion in 14 clinical trials for pancreatic adenocarcinoma, of which 8 are open and 6 are closed. Of the trials that contain ER Negative and pancreatic adenocarcinoma as inclusion criteria, 8 are phase 1 (5 open), 5 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 12 clinical trials for gastric adenocarcinoma, of which 10 are open and 2 are closed. Of the trials that contain ER Negative and gastric adenocarcinoma as inclusion criteria, 7 are phase 1 (5 open) and 5 are phase 1/phase 2 (5 open) [5].

ER Negative is an inclusion criterion in 12 clinical trials for head and neck carcinoma, of which 8 are open and 4 are closed. Of the trials that contain ER Negative and head and neck carcinoma as inclusion criteria, 9 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 12 clinical trials for soft tissue sarcoma, of which 6 are open and 6 are closed. Of the trials that contain ER Negative and soft tissue sarcoma as inclusion criteria, 8 are phase 1 (2 open) and 4 are phase 1/phase 2 (4 open) [5].

ER Negative is an inclusion criterion in 11 clinical trials for lymphoma, of which 6 are open and 5 are closed. Of the trials that contain ER Negative and lymphoma as inclusion criteria, 8 are phase 1 (4 open) and 3 are phase 1/phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 10 clinical trials for squamous cell lung carcinoma, of which 7 are open and 3 are closed. Of the trials that contain ER Negative and squamous cell lung carcinoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 9 clinical trials for glioblastoma, of which 5 are open and 4 are closed. Of the trials that contain ER Negative and glioblastoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 9 clinical trials for mesothelioma, of which 6 are open and 3 are closed. Of the trials that contain ER Negative and mesothelioma as inclusion criteria, 9 are phase 1 (6 open) [5].

ER Negative is an inclusion criterion in 9 clinical trials for pancreatic ductal adenocarcinoma, of which 5 are open and 4 are closed. Of the trials that contain ER Negative and pancreatic ductal adenocarcinoma as inclusion criteria, 6 are phase 1 (5 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (0 open) [5].

ER Negative is an inclusion criterion in 8 clinical trials for Merkel cell carcinoma, of which 7 are open and 1 is closed. Of the trials that contain ER Negative and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 4 are phase 1/phase 2 (4 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 7 clinical trials for prostate adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain ER Negative and prostate adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open) and 2 are phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 7 clinical trials for sarcoma, of which 4 are open and 3 are closed. Of the trials that contain ER Negative and sarcoma as inclusion criteria, 4 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 6 clinical trials for cholangiocarcinoma, of which 4 are open and 2 are closed. Of the trials that contain ER Negative and cholangiocarcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 6 clinical trials for clear cell renal cell carcinoma, of which 4 are open and 2 are closed. Of the trials that contain ER Negative and clear cell renal cell carcinoma as inclusion criteria, 5 are phase 1 (3 open) and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 6 clinical trials for nasopharyngeal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ER Negative and nasopharyngeal carcinoma as inclusion criteria, 5 are phase 1 (4 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 5 clinical trials for acute myeloid leukemia, of which 4 are open and 1 is closed. Of the trials that contain ER Negative and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 5 clinical trials for colorectal adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain ER Negative and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [5].

ER Negative is an inclusion criterion in 5 clinical trials for esophageal squamous cell carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ER Negative and esophageal squamous cell carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 5 clinical trials for high grade ovarian serous adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain ER Negative and high grade ovarian serous adenocarcinoma as inclusion criteria, 5 are phase 1 (4 open) [5].

ER Negative is an inclusion criterion in 5 clinical trials for skin squamous cell carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ER Negative and skin squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for cancer, of which 1 is open and 3 are closed. Of the trials that contain ER Negative and cancer as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain ER Negative and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain ER Negative and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for esophagogastric carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ER Negative and esophagogastric carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 3 are open and 1 is closed. Of the trials that contain ER Negative and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ER Negative and non-hodgkin lymphoma as inclusion criteria, 4 are phase 1 (4 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for non-squamous non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ER Negative and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 4 clinical trials for peritoneal mesothelioma, of which 1 is open and 3 are closed. Of the trials that contain ER Negative and peritoneal mesothelioma as inclusion criteria, 3 are phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for adenoid cystic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ER Negative and adenoid cystic carcinoma as inclusion criteria, 3 are phase 1 (2 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for biliary tract carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and biliary tract carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ER Negative and carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ER Negative and colon carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for cutaneous melanoma, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for ductal carcinoma in situ, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and ductal carcinoma in situ as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for esophageal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for inflammatory breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and inflammatory breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for lung adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ER Negative and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for malignant ovarian epithelial tumor, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and malignant ovarian epithelial tumor as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for malignant uterine neoplasm, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ER Negative and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 0 are open and 3 are closed. Of the trials that contain ER Negative and pleural mesothelioma as inclusion criteria, 3 are phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 3 clinical trials for thymic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ER Negative and thymic carcinoma as inclusion criteria, 3 are phase 1 (3 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain ER Negative and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for anal canal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for anal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and anal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain ER Negative and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for breast invasive ductal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and breast invasive ductal carcinoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for breast invasive lobular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and cervical squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for gallbladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and gallbladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain ER Negative and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ER Negative and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for malignant pleural mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for mixed lobular and ductal breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain ER Negative and myelodysplastic syndromes as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for neuroendocrine carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ER Negative and neuroendocrine carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for ovarian endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ER Negative and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for thymoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and thymoma as inclusion criteria, 2 are phase 1 (2 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 2 clinical trials for vulvar carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ER Negative and vulvar carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for adnexal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and adnexal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and B-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and benign breast neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for bilateral breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and bilateral breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and cervical carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and chordoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and double-hit lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and gastric diffuse adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and kidney carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for laryngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and laryngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and leiomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for lobular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and lobular breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for malignant uterine corpus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and malignant uterine corpus neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for medullary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and medullary breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and myxofibrosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and ovarian carcinosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for pleural biphasic mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and pleural biphasic mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for pleural epithelioid mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and pleural epithelioid mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for pleural mesothelioma, sarcomatoid type, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and pleural mesothelioma, sarcomatoid type as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and salivary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and tenosynovial giant cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, diffuse type, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and tenosynovial giant cell tumor, diffuse type as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ER Negative and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for urethral carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and urethral carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ER Negative is an inclusion criterion in 1 clinical trial for well-differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ER Negative and well-differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].